Potential treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases may already be out there in ...

Vanderbilt ALS Research Center (VARC) is using open science--pooling and sharing global research to help find a cure for ALS, ...

MNPD believes the fire started on the third floor of the parking garage and that the third through sixth floors are ...

Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corestemchemon Inc. is planning to file a BLA for Neuronata-R (lenzumestrocel) by the end of 2025 to gain accelerated ...

Experimental drug Ulefnersen offers hope for rare, early-onset Amyotrophic lateral sclerosis (ALS) in clinical trials.

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Usnoflast is an orally available small molecule that's designed to reduce inflammation, a key contributor to nerve cell ...

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Experimental drug Ulefnersen shows potential in halting and even reversing symptoms in patients with FUS- Amyotrophic lateral sclerosis (ALS) mutation One patient regained full motor function ...

Amyotrophic lateral sclerosis (ALS) is a progressive disease that causes severe weakness due to progressive degeneration of a specific set of motor nerves in the spinal cord. People with ALS will ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...